Episode 811
TWiV 811: COVID-19 clinical update #82 with Dr. Daniel Griffin
October 2, 202140m 26s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In COVID-19 clinical update #82, Daniel Griffin reviews vaccines for 5-12 years old, safety of a third vaccine dose, Oklahoma reinfection data, Regencov outcomes, Pfizer protease inhibitor, impact of Tocilizumab, and incidence of long COVID.
Hosts: Daniel Griffin and Vincent Racaniello
Subscribe (free): iTunes, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Data on Pfizer-BioNTech in 5-12 year olds (Pfizer)
- Safety of additional vaccine dose (MMWR)
- Oklahoma reinfection rates (OK DOH)
- Regencov outcomes (NEJM)
- Pfizer protease inhibitor trial (Pfizer)
- WHO recommends antibody therapy (Hosp Health)
- Tocilizumab use in hospitalized patients (Resp Care)
- Long COVID (PLoS Medicine)
- Letters read on TWiV 811
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]